BridgeBio Pharma Inc BBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BBIO is a good fit for your portfolio.
News
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
-
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
-
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
-
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
Trading Information
- Previous Close Price
- $24.98
- Day Range
- $24.29–25.24
- 52-Week Range
- $12.75–44.18
- Bid/Ask
- $24.59 / $24.67
- Market Cap
- $4.53 Bil
- Volume/Avg
- 1.2 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 436.59
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 556
- Website
- https://www.bridgebio.com
Comparables
Valuation
|
Metric
|
BBIO
|
VRDN
|
GBIO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.48 | 0.91 |
Price/Sales | 436.59 | 2,160.78 | 30.36 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BBIO
|
VRDN
|
GBIO
|
|---|---|---|---|
Quick Ratio | 3.04 | 17.93 | 6.73 |
Current Ratio | 3.32 | 18.26 | 6.83 |
Interest Coverage | −7.26 | −137.76 | — |
Quick Ratio
BBIO
VRDN
GBIO
Profitability
|
Metric
|
BBIO
|
VRDN
|
GBIO
|
|---|---|---|---|
Return on Assets (Normalized) | −96.99% | −42.76% | −25.96% |
Return on Equity (Normalized) | — | −82.42% | −40.85% |
Return on Invested Capital (Normalized) | −110.02% | −50.70% | −34.11% |
Return on Assets
BBIO
VRDN
GBIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tggjcvgrs | Cgpw | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lddfnclj | Ktkmwr | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jhkmnzpv | Vhwwyp | $98.1 Bil | |
MRNA
| Moderna Inc | Jlrksjlxm | Crpft | $39.1 Bil | |
ARGX
| argenx SE ADR | Tklnlhrr | Jdl | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Qbmnxnff | Qllq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tvmdybfk | Bzrdbn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wjnvrrfm | Wnhcxn | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dzgrynmrdm | Rbnqgtt | $12.5 Bil | |
INCY
| Incyte Corp | Mkpmwcsh | Xrhrjy | $11.9 Bil |